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Poster Session II S303population ranging up to 80% at an effector to target ratio of 40:1.
The LSC population however was found to be uniformly less sensi-
tive to NK cells than the non-LSC blast population, exhibiting apo-
ptosis that was 45-85% of the more mature population (p5 0.0002
at 10:1 effector-to-target ratio; p5 0.017 at 40:1 effector-to-target
ratio).
Conclusions: Immunophenotypically-defined AML stem cells show
a reduced sensitivity to killing by allogeneic NK cells, a result that
may be related to lower levels of expression of the activating ligands
MICA/B and CD48. These results may have implications for the
utility of natural killer cells in eradicating AML.394
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Chronic graft versus host disease (CGHD) remains a major non-
relapse source of morbidity and mortality following allogeneic
hematopoietic stem cell transplantation (HSCT), but little is known
of its pathogenesis. As part of an ongoingNCI CGVHDnatural his-
tory protocol (04-C-0281), paired affected and unaffected skin biop-
sies were collected from patients with cutaneous CGVHD. Using
multi-parameter fluorescent immunohistochemistry, we assessed
the dense subepidermal infiltrate of mononuclear cells in skin biop-
sies with lichenoid histological findings in 9 patients. The primary T
cell population in affected skin biopsies consisted of Th1/Tc1 cells
expressing the transcription factor T-Bet. CD8 +T cells predomi-
nated in tissue from patients fewer than 9 months after HSCT, but
were less than CD8-CD3+ cells in biopsies taken from patients
more than one year after HSCT. Both CD68+ myeloid cells in the
dermal infiltrate and epidermal keratinocytes expressed elevated
levels of Interferon (IFN) inducible factors, including MxA and the
chemokineMIG (CXCL9). Concomitantly, most T cells in the infil-
trate expressed the T-Bet induced receptor CXCR3 that bindsMIG.
These findings are consistent with a pathogenic process in which
IFN produced by keratinocytes and infiltrating myeloid elements
could support the recruitment of CXCR3+ effector cells into the
skin. Elevated levels of IFN-inducible factors are also evident sys-
temically. When cells from normal donors were cultured with as
little as 2 pg/ml of Type I IFN,mRNA expression of the IFN-induc-
ible genes BAFF, MxA and IFI44 increased by 2 to 4 logs. Plasma
levels of the IFN-inducible factors MIG and BAFF were elevated
in these patients (MIG median 1813 pg/ml; range 125-7440; BAFF
median 4512; range 1453-14907 pg/ml) compared with normal
donors. These data, and comparable observations we have made in
oral CGVHD (Imanguli, Blood, 2009), support the hypothesis that
IFN-mediated processes contribute to epithelial tissue damage in
CGVHD.395
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We have previously demonstrated that activation of STAT1 and
STAT3 in GVHD target tissues and secondary lymphoid organs be-
long to the earliest events during induction of GVHD. Using
STAT1-gene-deficient (STAT1KO) mice we tested the role of do-
nor STAT1 during GVHD induction in fully MHC-mismatched
(129Sv[H2b] to BALB/c [H2d]) and MHC-matched minor histo-
compatibility antigen (mHA)-mismatched BMT (129Sv[CD45.2,
H2b] to B6 [H2b] or B6.SJL [CD45.1, H2b] following lethal irradi-
ation. Using STAT1KO whole splenocytes we were able to showthat lack of STAT1 significantly inhibited development of GVHD
in both major and mHAmismatched recipients with significantly ex-
tended median survival times (MST), lower GVHD morbidity and
less inflammation in GVHD target tissue samples. Protection
against GVHD in recipients of STAT1KO splenocytes was associ-
ated with significant inhibition of T cell activation as determined
by changes in CD25, CD69 and CD62L expression on donor
CD4+ and CD8 + T cells on days +6 post-BMT. Lack of STAT1
in donor splenocytes resulted in a significantly attenuated and
skewed systemic inflammatory response on day +6 post-BMT as
demonstrated by significantly reduced IFN-g levels (p\0.05), but
significantly increased IL-4 (p5 0.003), IL-5 (p5 0.007) and IL-
17 (p5 0.03) levels. In vitro studies demonstrated that STAT1KO
CD8 +T cells produced much less IFN-g upon combined engage-
ment of TCR and costimulation, but that this decrease in IFN-g se-
cretion could be rescued if cells were simultaneously cultured under
Th1 conditions (i.e. in the presence of IL-12 and anti-IL4 antibody).
In contrast, lack of STAT1 completely inhibited the differentiation
of naive CD4 + T cells to IFN-g-producing cells upon TCR
commitment and this capacity was also severely impaired under
Th1 conditions. These findings were confirmed in vivo in the
MHC-mismatched GVHD setting as we were able to observe a sig-
nificantly reduced number of donor-derived CD4 + IFN-g-produc-
ing cells in recipients of STAT1 KO (p5 0.018) compared to
recipients of WT cells, while there was no difference with regard
to IFN-g expression in CD8 +T cells. Most importantly, we ob-
served a significant expansion of CD4 +CD25 + FOXP3 +Treg cells
in recipients of STAT1KO splenocytes in both major MHC-mis-
matched and MHC-matched mHA-mismatched setting. Currently,
studies are ongoing to assess the role of STAT1 in the generation
and function of Treg cells during GVHD.396
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Regulatory CD4 + FOXP3 +T-cells (FOXP3 +Treg) are sug-
gested to play a role in control of allo-reactive disease after haema-
topoietic stem cell transplantation (HSCT). We analyzed
FOXP3 +Treg in relation to allo-reactive disease after cord blood
(u-CB), matched unrelated donor (MUD) or identical sibling (id-
Sib) HSCT.
In this prospective cohort study, absolute CD4 +T-cell numbers
and the ratio of FOXP3 +Treg of total CD4 + T-cells were analyzed
every other week by direct whole blood Fluorescence-activated cell
sorting analysis. Early allo-reactive disease (\100days) was defined
as acute Graft-versus-Host-Disease and/or idiopathic pulmonary
syndrome after HSCT.
A total of 32 pediatric patients were included. Following myeloa-
blative conditioning, 7 (22%) patients received aMUD, 13 (41%) id-
Sib and 12 (38%) u-CB HSCT. These three patient groups showed
significant differences in the FOXP3 +Treg reconstitution pattern.
The FOXP3 +Treg/CD4+ ratio was higher in the first 6 weeks after
id-Sib-HSCT compared to u-CB or MUD HSCT (p5 0.018). In
u-CB recipients, the FOXP3 +Treg reconstitution was relatively
slow. 12 of the 32 patients developed allo-reactive disease (8 aGvHD
and 4 IPS). Overall, FOXP3 +Treg/CD4+ ratios were lower in
patients prior to the developed allo-reactive disease compared to
patients without allo-reactive disease (p5 0.010).
Development of allo-reactive disease is preceded by a low ratio of
FOXp3 + Treg/CD4 + early after HSCT. The FOXP3 +Treg/CD4
ratio early (6 weeks) after HSCTmight be used to identify patients at
risk for allo-reactive disease and to guide immunosuppressive or im-
muno-therapy. Influencing the ratio of FOXP3 +Treg/CD4+ in vivo
may influence the incidence of allo-reactive disease and may make
HSCT safer.
